CEL-SCI Corp. (CVM)

8.48
AMEX : Health Technology
Prev Close 8.54
Day Low/High 8.48 / 8.72
52 Wk Low/High 2.37 / 9.64
Avg Volume 760.60K
Exchange AMEX
Shares Outstanding 35.05M
Market Cap 299.37M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Corporation Reports Third Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2019.

Noteworthy Monday Option Activity: CVM, CISN, ARMK

Noteworthy Monday Option Activity: CVM, CISN, ARMK

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CEL-SCI Corporation , where a total of 3,691 contracts have traded so far, representing approximately 369,100 underlying shares. That amounts to about 65.4% of CVM's average daily trading volume over the past month of 564,680 shares.

First Week Of CVM September 20th Options Trading

First Week Of CVM September 20th Options Trading

Investors in CEL-SCI Corporation saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CVM options chain for the new September 20th contracts and identified the following call contract of particular interest.

CEL-SCI's Scientific Review On Inflammatory Disease Therapies Published In Peer Reviewed Journal "International Immunopharmacology"

CEL-SCI's Scientific Review On Inflammatory Disease Therapies Published In Peer Reviewed Journal "International Immunopharmacology"

CEL-SCI Corporation (NYSE American: CVM) today announced that a review titled, " Lessons From Next Generation Influenza Vaccines For Inflammatory Disease Therapies" was published in the peer reviewed scientific Journal International Immunopharmacology.

Noteworthy Monday Option Activity: CVM, LPX, SBUX

Noteworthy Monday Option Activity: CVM, LPX, SBUX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CEL-SCI Corporation , where a total of 4,302 contracts have traded so far, representing approximately 430,200 underlying shares. That amounts to about 40.7% of CVM's average daily trading volume over the past month of 1.1 million shares.

CEL-SCI Collaborators Presents Data For New Vaccine In The Treatment Of Rheumatoid Arthritis At The International Conference On Immunity And Immunochemistry Meeting

CEL-SCI Collaborators Presents Data For New Vaccine In The Treatment Of Rheumatoid Arthritis At The International Conference On Immunity And Immunochemistry Meeting

CEL-SCI Corporation (NYSE American: CVM) announced that one of its key collaborators from Rush University Medical center, Dr.

CEL-SCI Corporation Set To Join Russell 3000® Index

CEL-SCI Corporation Set To Join Russell 3000® Index

CEL-SCI Corporation (NYSE American: CVM) is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions...

CEL-SCI Corporation To Present At The 9th Annual LD Micro Invitational

CEL-SCI Corporation To Present At The 9th Annual LD Micro Invitational

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9 th annual LD Micro Invitational on Tuesday, June 4 th at 10:40 a.

CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2019.

CEL-SCI Presents New Data For Its LEAPS Vaccine In The Treatment Of Rheumatoid Arthritis At The American Association Of Immunologists 103rd Annual Meeting

CEL-SCI Presents New Data For Its LEAPS Vaccine In The Treatment Of Rheumatoid Arthritis At The American Association Of Immunologists 103rd Annual Meeting

CEL-SCI Corporation (NYSE American: CVM) announced today that Daniel Zimmerman, Ph.

CEL-SCI Corporation Releases Letter To Shareholders

CEL-SCI Corporation Releases Letter To Shareholders

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders: Dear CEL-SCI Shareholders: The first 4 months of this year have already been very positive for us.

IIROC Trading Halt - CVM

IIROC Trading Halt - CVM

VANCOUVER, May 7, 2019 /CNW/ - The following issues have been halted by IIROC: Company: CVR Medical Corp TSX-Venture Symbol: CVM (All Issues) Reason: Cease Trade Order Halt Time (ET): 8:15 AM IIROC can make a decision to impose a temporary suspension...

CEL-SCI To Present At The ThinkEquity Conference

CEL-SCI To Present At The ThinkEquity Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the ThinkEquity Conference in New York, NY on Thursday, May 2, 2019 at 1:00 p.

First Week Of CVM June 21st Options Trading

First Week Of CVM June 21st Options Trading

Investors in CEL-SCI Corporation saw new options become available this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CVM options chain for the new June 21st contracts and identified the following call contract of particular interest.

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection)...

CEL-SCI Corporation Releases Letter To Shareholders

CEL-SCI Corporation Releases Letter To Shareholders

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting: Dear CEL-SCI Shareholders: The enrollment of 928 patients in our Phase 3 clinical trial of Advanced Primary (just diagnosed and...

CEL-SCI Selected By National Institutes Of Health To Showcase Its LEAPS Technology At BIO International Convention

CEL-SCI Selected By National Institutes Of Health To Showcase Its LEAPS Technology At BIO International Convention

CEL-SCI Corporation (NYSE American: CVM) today announced it has been selected by the U.

CEL-SCI's Scientific Article On Vaccines For Autoimmune Disease Published In Journal Of Clinical & Cellular Immunology

CEL-SCI's Scientific Article On Vaccines For Autoimmune Disease Published In Journal Of Clinical & Cellular Immunology

CEL-SCI Corporation (NYSE American:CVM) today announced the Journal of Clinical & Cellular Immunology has published an article titled, "Why Don't We Have a Vaccine Against Autoimmune Diseases?" co-written by Dr.

CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2018.

CEL-SCI To Present At 2019 BIO CEO & Investor Conference

CEL-SCI To Present At 2019 BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at...

U.S. Patent Office Issues CEL-SCI Two Patents For Its LEAPS Vaccine Platform Technology

U.S. Patent Office Issues CEL-SCI Two Patents For Its LEAPS Vaccine Platform Technology

CEL-SCI Corporation (NYSE American: CVM) today announced the U.S.

CEL-SCI Regains Full Listing Compliance With NYSE American

CEL-SCI Regains Full Listing Compliance With NYSE American

CEL-SCI Corporation (NYSE American: CVM) today announced that it has received notification from the staff of the NYSE American, its current listing exchange, that the Company is now considered in full compliance with the continued listing requirements.

CEL-SCI Reports Fiscal 2018 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2018 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2018.

CEL-SCI Receives About $8 Million From Warrant Exercises

CEL-SCI Receives About $8 Million From Warrant Exercises

CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the Company's common stock during the past 3 months.

CEL-SCI Announces Warrants To Expire On October 11, 2018

CEL-SCI Announces Warrants To Expire On October 11, 2018

CEL-SCI Corporation (NYSE American: CVM) is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.

CEL-SCI Receives $5.4 Million From Warrant Exercises

CEL-SCI Receives $5.4 Million From Warrant Exercises

CEL-SCI Corporation (NYSE American: CVM) announced today it has received $5,435,367 through the exercise of warrants to purchase shares of the Company's common stock during August through September 13, 2018.

NIH Selects CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine For Commercialization Accelerator Program

NIH Selects CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine For Commercialization Accelerator Program

CEL-SCI Corporation (NYSE American: CVM) announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer...

CEL-SCI Corporation Releases Letter To Shareholders

CEL-SCI Corporation Releases Letter To Shareholders

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting: Dear CEL-SCI Shareholders, Our singular goal right now is to reach the final data readout of the Phase 3 trial to establish the...